We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Retrotope

News List

FDA Grants Orphan Drug Designation for Progressive SupraNuclear Palsy Treatment americanpharmaceuticalreview
March 09, 2020
Retrotope announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug (RT001) ...
Retrotope Announces First Dosing of RT001 in Friedreich’s Ataxia Study americanpharmaceuticalreview
January 15, 2020
Retrotope has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of the inherited ataxias. RT001, a stabilized fatty acid drug, has been shown to reduce lipid peroxidation leading to cell death in ...